Online inquiry

IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9397MR)

This product GTTS-WQ9397MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PTPRC gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001267798.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5788
UniProt ID P08575
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9397MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15112MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ2112MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ6405MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CT-011
GTTS-WQ8420MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HSP90mab
GTTS-WQ8627MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ929MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ7336MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FPA-150
GTTS-WQ8005MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GZ-402668
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW